Discussion Forum

Dear All, We are looking for group opinions and feedback on the use of 'Administration of drug (procedure)' versus 'Drug therapy (procedure)' concepts.  An overview of the topic was presented in the Seoul meetings in Oct 2024 - including detailed background and logging of use-cases. The presentation is attached to this thread.  A recent content request has highlighted the challenge in the area:  68322007 |Administration of antibiotic (procedure)| was added to the terminology in 202209

Hello! I am wondering whether it would be possible to include preferred term in a specifc language when extracting the mappning file from Snap2Snomed? If not I wonder if it would be possible to add this functionality to an upcoming upsate of Snap2Snomed? It would be greatly benficial to us since in most of our use cases in sweden we need a list consisting of Snomed CT ID + PT in Swedish and currently the platform only gives FSN and Snomed CT id with the export file.

Infoway Request for Drug Model enhancements_DEUSG_LP_LB_20250619 (Hydration).pptx Dear All, Following up from todays DEUSG meeting please use this discussion space for sharing proposals and options for managing hydration subsumption in advance of the next meeting. Regards, Shane

This is a follow-up to the discussion on the April 9th, 2025 DEUSG Meeting. Key Points: Discussing the difference between the dose form intended sites, and routes of administration. Evaluating whether these can use the same list of concepts in SNOMED CT. Considering the mapping to different EDQM code lists. Considerations: Dose form intended sites refer to the locations where a medication is applied or administered. Routes of administration describe the path by which a drug ente

Hi All, As a follow up to our DEUSG meeting last week please use this discussion thread for any feedback on an different strength representations being used in the drug model. Presentation is attached to bottom of meeting notes here: https://confluence.ihtsdotools.org/display/USRG/2025-03-13%3A+Virtual https://confluence.ihtsdotools.org/display/USRG/2025-03-13%3A+Virtual    Thanks to Australia for the feedback and presentation. Regards, Shane

Hi All, As a follow up to our DEUSG meeting last week please use this discussion thread for any feedback on an additional 'BoSS Clinical Drug' concept potentially being added to the drug model. Presentation on slide 22 here: https://drive.google.com/file/d/1uuxCV5yL1goTI03tRlPkSXErNJAJN_zK/view https://drive.google.com/file/d/1uuxCV5yL1goTI03tRlPkSXErNJAJN_zK/view  and link to meeting recording here: 2025-02-20: Virtual - User Support Reference Group - SNOMED Confluence https://confluence

Hi All, As a follow up to our DEUSG meeting last week please use this discussion thread for any feedback on additional attributes being added to the MRCM for use in national drug extensions. Presentation here: https://drive.google.com/file/d/1mA4JuuPY7-QEHDOUXjeA7zlvJmnBJybW/view https://drive.google.com/file/d/1mA4JuuPY7-QEHDOUXjeA7zlvJmnBJybW/view and link to meeting recording here: 2025-02-20: Virtual - User Support Reference Group - SNOMED Confluence https://confluence.ihtsdotools.org/

Proposal for change to medicinal products by changing the /1 hour normalization of patch products to usual manufacturer’s stated strength commonly /24 hours (or /1 hour or /16 hours or /72 hours may be appropriate). Do we have consensus in the DEUSG about how this should be represented in the international edition? For example, concentration strength (eg. moving away from normalized /1) or presentation strength - how would this work? - or something else (rate etc)? BN 20241007_ patches str

Please provide comments on the examples below representing the challenges in harmonizing the US Drug Extension with SNOMED CT international release introduced during the 2025-02-20 DEUSG meeting.  Complete details can be found at 2025-02-20: Virtual.  Slides can be found at: https://drive.google.com/file/d/1rkpoLnmKMecO1Bi5xGJVteT2miJy2vZ0/view https://drive.google.com/file/d/1rkpoLnmKMecO1Bi5xGJVteT2miJy2vZ0/view. Recording starts at 55:00.   Summary of 5 examples: Thiothixene: SNOMED has

I hope this is the right place! Clarity around content authored in an extension and then promoted to be included in the International Release. What to do with description IDs, relationship IDs, and language IDs.